we aim to cure immune diseases
is addressing today’s medical demands for the treatment of allergy and autoimmune diseases. Today’s treatment options exhibit shortcomings in the fields of safety, effectiveness and patient compliance.
Tolerogenics S.à.r.l. is a public-private-partnership venture with the Luxembourg Institute of Health (LIH), a centre of scientific excellence in the field of immunology. The company was founded in July 2016.
Tolerogenics S.à.r.l. is providing a novel tolerance-based approach to enable a safe, efficient and lasting cure of allergy and autoimmune diseases with patient-friendly treatment protocol. For the induction of tolerance, Tolerogenics S.à.r.l. has developed novel and patent protected key technologies, which can be used in combination with established allergen/autoantigen-specific immunotherapy or to develop new treatment options.
Cure – not only treatment of symptoms. Tolerogenics S.à.r.l. aims to become an international leading company in the development of the most effective therapy options for allergy and autoimmune diseases. We believe in our creative scientists and sophisticated management to help patients worldwide living a better life.
Changing the game. Tolerogenics S.à.r.l. has developed several key technologies to overcome today’s bottlenecks in immunotherapy treatment. Tolerogenic’s has used these technologies to create a novel patent-protected approach of tolerance induction to achieve long-term cure of allergy diseases. The experienced management of Tolerogenics will provide the strategic and regulatory support to bring the products to market.
for safe, effective and long-lasting relief from immune diseases
Allergen-specific immunotherapy (AIT)
of Tolerogenics S.à.r.l. approach is based on state-of-the-art knowledge of the immune system. Today it is known that the immune system represents a complex network of triggers and controls with remarkable plasticity. In the normal state the immune system is in healthy balance. However, in diseases this balance is often lost and the natural control mechanisms are suppressed. One of the most effective control elements in the immune system are regulatory T cells (Tregs). Immune diseases can be simplified seen as an imbalance of Tregs and disease-related effector T cells (Teff, see graphic on right). The tolerance-based approach of Tolerogenics aims at effectively reinstalling the controlling function of Treg on the immune status.
Modulating immune responses
In principle, present AIT is based on two different approaches. One approach is to modulate TH2-based allergy towards a TH1 (inflammatory)-based immune response to block allergy-related IgE with allergen-specific IgG1 antibodies. While this approach provides relief to allergic patients, it is not directed towards the induction of lasting tolerance.
The other approach aims to induce tolerance by a administration of allergens or allergen-derived peptides for an extended period of time up to several years. While this approach has the potential of restoring immunological tolerance, the therapeutic efficiency is limited. Supporting tolerance-promoting strategies are required to boost the therapeutic efficacy of the approach.
The novel approach of Tolerogenics is based on a patent-protected technology, capable of inducing allergen-specific tolerance in peripheral dendritic cells (DCs) with high efficacy, which in turn, enhances the Treg population so it can regain control of the immune system.
The novel approach of Tolerogenics is unique in that it combines high therapeutic efficacy with safety and short treatment periods which will improve compliance of patients significantly.
related to tolerance induction
Hydrogel drug delivery
Subcutaneously injected thermosensitive hydrogels provide sustained drug delivery and efficient immune system modulation. Read more about our ImmunoGel technology…
PLGA nanoparticles as tolerance-promoting adjuvant
Hydrogel-embedded plain PLGA nanoparticles are used as tolerance-inducing adjuvant. Read more about our ToleroSphere technology…
Hydrogel-mediated “find-me” molecules are used to recruit peripheral antigen-presenting cells (APC) for enhanced phagocytosis of hydrogel-embedded allergens or autoantigens. Read more about our PhagoAttract technology…
PS-liposomes as tolerance-promoting adjuvant
Hydrogel-embedded phosphatidylserine (PS)-liposomes mimic tolerance-promoting apoptotic cells and are used for dendritic cell (DC)-targeting and as tolerance-inducing adjuvant. Read more about our ToleroPrime technology…
Hydrogel-embedded PS-liposomes loaded with DC-maturation inhibitors are used to target DCs and to to convert them effectively into tolerogenic DCs (tolDCs). Read more about our ToleroPrime technology…
Peptide-loaded tolerogenic PS-liposomes
Hydrogel-embedded PS-liposomes loaded with antigen-derived T cell peptides are used for effective targeting of antigen-presenting cells (APCs) and presentation of the peptides to T cells. Read more about our ToleroAIT technology…
be part of the success story
Participate in success.
Tolerogenics S.à.r.l. is inviting capital investment companies to participate in our company and projects. We are open for interested companies to join our effort to become a “game changer” in today’s immune disease market.
At present the market is dominated by costs of symptomatic treatments. However, allergen/autoantigen-specific immunotherapies (AIT) are the only curative approach in immune disease treatment. Ask yourself why immunotherapies only make up 6% of the allergy market share? And why is there no AIT for autoimmune diseases (e.g. rheumatoid arthritis, multiple sclerosis, etc.)? Because there is a huge demand for improvement! Contact us…